索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]张航,安景辉,石凤梧.经导管主动脉瓣置换术后抗栓治疗策略[J].国际心血管病杂志,2022,01:41-43.
点击复制

经导管主动脉瓣置换术后抗栓治疗策略(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年01期
页码:
41-43
栏目:
综述
出版日期:
2022-02-10

文章信息/Info

Title:
-
作者:
张航; 安景辉; 石凤梧
作者单位：050000 石家庄，河北医科大学第二医院心脏外科
Author(s):
-
关键词:
经导管主动脉瓣置换术; 抗栓; 亚临床瓣膜血栓
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.01.011
文献标识码:
-
摘要:
目前，经导管主动脉瓣置换术（TAVR）后抗栓治疗方案尚不统一，因此为 TAVR 术后患者选择最佳的抗栓策略，实现个体化的抗栓治疗就成为了当前TAVR 术后患者 管理的重要内容。术后选择双联抗血小板、单药抗血小板和（或）抗凝治疗是目前TAVR 术后抗栓治疗的主要策略。一方面目前 TAVR 适应证人群常合并肝肾功能不全、冠状动脉 粥样硬化性心脏病、糖尿病、肿瘤、心房颤动等出血或血栓形成的高危因素，另一方面以术 后影像学表现为主导的亚临床血栓是否需要更安全积极的抗栓方案尚无明确临床研究证据。 该文探讨并梳理了T
Abstract:
-

参考文献/References

[1] 殷伟贤, 李永在, 魏峥. 经导管主动脉瓣膜植入术:进展与现 状[J]. 中国心血管杂, 2014, 19(5):338-340.
[2] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Circulation, 2017, 135(25):e1159-e1195.
[3] Falk V, Baumgartner H, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease[J]. Eur J Cardiothorac Surg, 2017, 52(4):616-664.
[4] 中国医师协会心血管内科医师分会结构性心脏病专业委员 会. 经导管主动脉瓣置换术中国专家共识(2020 更新版)[J]. 中国介入心脏病学杂志, 2020, 28(6):301-309.
[5] 左文杰, 马根山. 经导管主动脉瓣置换术后抗栓治疗的研究 进展[J]. 中国循环杂志, 2019, 34(11):1138-1141.
[6] Aryal MR, Karmacharya P, Pandit A, et al. Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis[J]. Heart Lung Circ, 2015, 24(2):185-192.
[7] Piayda K, Mohring A, Dannenberg L, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve[J]. JACC Cardiovasc Interv, 2017, 10(15):1598.
[8] Rodes-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin ＋ clopidogrel following transcatheter aortic valve implantation) randomized clinical trial[J]. JACC Cardiovasc Interv, 2017, 10(13):1357-1365.
[9] Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation[J]. N Engl J Med, 2020, 382(18):1696-1707.
[10] Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation[J]. N Engl J Med, 2020, 383(15):1447-1457.
[11] Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves[J]. N Engl J Med, 2015, 373:2015–2024.
[12] Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications[J]. Am Coll Cardiol, 2016, 68(19):2059- 2069.
[13] Sondergaard L, Backer OD, Kofoed KF, et al. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves[J]. Eur Heart J, 2017, 38(28):2201- 2207.
[14] Huynh K. Thrombosis: leaflet motion after TAVI or SAVR[J]. Nat Rev Cardiol, 2015, 12(12):683.
[15] Ruile P, Jander N, Blanke P, et al. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation[J]. Clin Res Cardiol, 2017, 106(2):85-95.
[16] Sherwood MW, Vora AN. Challenges in aortic stenosis: review of antiplatelet/anticoagulant therapy management with transcatheter aortic valve replacement (TAVR): TAVR with recent PCI，TAVR in the patient with atrial fibrillation，and TAVR thrombosis management[J]. Curr Cardiol Rep, 2018, 20(12):130.
[17] Sondergaard L, De Backer O, Kofoed KF, et al. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves[J]. Eur Heart J, 2017, 38(28):2201- 2207.
[18] Dangas GD, Tijssen JGP, W?hrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic valve replacement[J]. N Engl J Med, 2020, 382(2):120-129.
[19] De Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement t[J]. N Engl J Med, 2020, 382(2):130-139.
[20] 赵振刚, 陈飞, 陈茂. 心脏瓣膜病的介入治疗进展[J]. 华西医 学, 2020, 35(4):401-405.

备注/Memo

备注/Memo:
通信作者：石凤梧， E-mail:shifengwu65@163.com
更新日期/Last Update: 2022-02-10